In this Editorial we discuss potential reasons for the negative results of the German Multicenter EPO Stroke Trial, which contrasted the findings of a clinical pilot trial and several preclinical studies that showed beneficial effects of EPO [2,3]. The gene discussed is EPO; the disease is stroke disorder.